Biomarkers Beyond the Natriuretic Peptides for Chronic Heart Failure: Galectin-3 and Soluble ST2
نویسنده
چکیده
B-type natriuretic peptide (BNP) and NT-proBNP are widely used plasma biomarkers for the diagnosis of acute decompensated heart failure and prognosis for future cardiac disease. The clinical performance of these tests for management of chronic heart failure is somewhat limited by the markers' high biological variation. Biomarkers such as galectin-3 and soluble ST2 that reflect ongoing remodeling via cardiac fibrosis of the heart may provide complementary information to the natriuretic peptides in the management of chronic heart failure with regards to risk stratification for future adverse cardiac events (death, myocardial infarction, and need for heart transplantation). However, implementation of these biomarkers into routine clinical practice requires documentation that these tests will enable therapeutic decisions that can be made to improve clinical outcomes, and the availability of commercial assays. This report will discuss the need for novel heart failure biomarkers, ideal characteristics of assays, and review and compare the clinical performance of assays for galectin-3 and sST2 for chronic heart failure disease management.
منابع مشابه
ST2 and Galectin-3: Ready for Prime Time?
ST2 and galectin-3 are emerging biomarkers in the field of heart failure and have been extensively studied, and that whether they provide additional prognostic value on top of the clinical models and the gold standard in HF, (NT-pro)BNP. Our aim was to provide a comprehensive review of these emerging HF-related biomarkers in chronic, acute and incident heart failure. Regardless of the type of h...
متن کاملA Multiparametric Approach Based on NT-proBNP, ST2, and Galectin3 for Stratifying One Year Prognosis of Chronic Heart Failure Outpatients
Galectin-3 and ST2 are emerging biomarkers involved in myocardial fibrosis. We evaluate the relevance of a multiparametric biomarker approach based on increased serum levels of NT-proBNP, galectin-3, and ST2 in stratifying the prognosis of chronic heart failure (CHF) outpatients. In 315 CHF outpatients in stable clinical condition clinical and echocardiographic evaluations were performed. Routi...
متن کاملBiomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure.
OBJECTIVES The aim of this study was to determine whether biomarkers of myocardial stress and fibrosis improve prediction of the mode of death in patients with chronic heart failure. BACKGROUND The 2 most common modes of death in patients with chronic heart failure are pump failure and sudden cardiac death. Prediction of the mode of death may facilitate treatment decisions. The relationship b...
متن کاملDoes Growth-Differentiation Factor-15 Provide Additional Prognostic Information Beyond Conventional Cardiovascular Risk Factors and Biomarkers in Heart Failure?
Heart failure (HF) is reported as a leading cause of premature cardiovascular (CV) death and increased hospitalization rate in patients with established CV disease [1, 2]. Although frequency of newly diagnosed HF in developed countries exhibits a trend to decrease, there is evidence regarding steadily growth of HF patients’ population worldwide [3]. Biological markers are widely used to stratif...
متن کاملSoluble ST2 and Galectin-3: What We Know and Don’t Know Analytically
The proteins soluble ST2 (sST2) and galectin-3 are currently gaining mounting interest as candidate biomarkers in cardiac disease. Both, sST2 and galectin-3 have been included in the 2013 ACCF/AHA guideline for additive risk stratification of patients with acute and chronic heart failure. The aim of this review is to provide information on analytical considerations of measuring circulating sST2...
متن کامل